Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för dasabuvir. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

8 träffar

Bibliografisk träff 2015-03-01

Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.

Sulkowski MS, Eron JJ, Wyles D, Trinh R, Lalezari J, Wang C, Slim J, Bhatti L, Gathe J, Ruane PJ, Elion R, Bredeek F, Brennan R, Blick G, Khatri A, Gibbons K, Hu YB, Fredrick L, Schnell G, Pilot-Matias T, Tripathi R, Da Silva-Tillmann B, McGovern B, Campbell AL, Podsadecki T.

JAMA · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1001/jama.2015.1328

Bibliografisk träff 2015-02-13

Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.

Klibanov OM, Gale SE, Santevecchi B.

Ann Pharmacother · review; journal article · DOI 10.1177/1060028015570729

Bibliografisk träff 2015-02-09

Dasabuvir : a new direct antiviral agent for the treatment of hepatitis C.

Trivella JP, Gutierrez J, Martin P.

Expert Opin Pharmacother · research-article; journal article · DOI 10.1517/14656566.2015.1012493

Bibliografisk träff 2015-01-31

Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir.

Menon RM, Badri PS, Wang T, Polepally AR, Zha J, Khatri A, Wang H, Hu B, Coakley EP, Podsadecki TJ, Awni WM, Dutta S.

J Hepatol · research support, non-u.s. gov't; multicenter study; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1016/j.jhep.2015.01.026

Bibliografisk träff 2015-01-16

Holkira (Ombitasvir/Paritaprevir/ Ritonavir with Dasabuvir) and Harvoni (Ledipasvir/Sofosbuvir) for Chronic Hepatitis C: A Review of the Clinical Evidence

Författaruppgift saknas

Tidskrift saknas · review

Bibliografisk träff 2015-01-12

ABT-450: a novel agent for the treatment of CHC genotype 1: focus on treatment-experienced patients.

Gamal N, Vitale G, Andreone P.

Expert Rev Anti Infect Ther · research support, non-u.s. gov't; review; journal article · DOI 10.1586/14787210.2015.1001746

Bibliografisk träff 2014-12-22

In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor.

Kati W, Koev G, Irvin M, Beyer J, Liu Y, Krishnan P, Reisch T, Mondal R, Wagner R, Molla A, Maring C, Collins C.

Antimicrob Agents Chemother · research-article; journal article · DOI 10.1128/aac.04619-14

Bibliografisk träff 2014-11-02

Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis C virus genotype 1 infection in the AVIATOR study.

Poordad F, Agarwal K, Younes Z, Cohen D, Xie W, Podsadecki T.

Clin Infect Dis · research support, non-u.s. gov't; journal article · DOI 10.1093/cid/ciu865